journal article·2024-03Open access

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models

Yanjun Zhang, Jing Sun, Jian Zheng, Suxiang Li, Haiyue Rao, Jun Dai, Zhaoyong Zhang, Yanqun Wang, Donglan Liu, Zhao Chen, Wei Ran, Airu Zhu, Fang Li, Qihong Yan, Yiliang Wang, Kuai Yu, Shengnan Zhang, Dong Wang, Yanhong Tang, Banghui Liu, Linling Cheng, Jiandong Huo, Stanley Perlman, Jingxian Zhao, Jincun Zhao

Advanced Science· Volume 11· Issue 9

Abstract

Abstract To combat SARS‐CoV‐2 variants and MERS‐CoV, as well as the potential re‐emergence of SARS‐CoV and spillovers of sarbecoviruses, which pose a significant threat to global public health, vaccines that can confer broad‐spectrum protection against betacoronaviruses (β‐CoVs) are urgently needed. A mosaic ferritin nanoparticle vaccine is developed that co‐displays the spike receptor‐binding domains of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 Wild‐type (WT) strain and evaluated its immunogenicity and protective efficacy in mice and nonhuman primates. A low dose of 10 µg administered at a 21‐day interval induced a Th1‐biased immune response in mice and elicited robust cross‐reactive neutralizing antibody responses against a variety of β‐CoVs, including a series of SARS‐CoV‐2 variants. It is also able to effectively protect against challenges of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 variants in not only young mice but also the more vulnerable mice through induction of long‐lived immunity. Together, these results suggest that this mosaic 3‐RBD nanoparticle has the potential to be developed as a pan‐β‐CoV vaccine.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Animal Virus Infections Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health the First Affiliated Hospital of Guangzhou Medical University Guangzhou 510300 P. R. China

Department of Microbiology and Immunology University of Iowa Iowa City IA 52242 USA

Guangzhou Customs District Technology Center Guangzhou 510700 P. R. China

State Key Laboratory of Respiratory Disease Guangdong Laboratory of Computational Biomedicine Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences Guangzhou 510530 P. R. China

Guangzhou laboratory Bio‐island Guangzhou 510320 P. R. China

Institute of Infectious disease Guangzhou Eighth People's Hospital of Guangzhou Medical University Guangzhou 510060 P. R. China

Institute for Hepatology National Clinical Research Center for Infectious Disease Shenzhen Third People's Hospital the Second Affiliated Hospital School of Medicine Southern University of Science and Technology Shenzhen 518112 P. R. China

Shanghai Institute for Advanced Immunochemical Studies School of Life Science and Technology ShanghaiTech University Shanghai 201210 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Basic and Applied Basic Research Foundation of Guangdong Province · Guangdong Medical Research Foundation

References (41)

Show source-provided references
1. 10.1002/rmv.228210.1002/rmv.2282 ↗
2. 10.1016/j.jaut.2020.10243410.1016/j.jaut.2020.102434 ↗
3. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
4. Supasa P. · Cell. · 2021
5. 10.1016/j.cell.2021.06.02010.1016/j.cell.2021.06.020 ↗
6. Zhou D. · Cell. · 2021
7. 10.1016/j.cell.2021.02.03210.1016/j.cell.2021.02.032 ↗
8. 10.1016/j.cell.2021.12.04610.1016/j.cell.2021.12.046 ↗
9. Tuekprakhon A. · Cell. · 2022
10. Cao Y. · Nature. · 2022
11. 10.1016/j.bcp.2016.05.00110.1016/j.bcp.2016.05.001 ↗
12. Sadeghalvad M. · RevMed. Virol. · 2022
13. 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5 ↗
14. 10.1126/science.abd232110.1126/science.abd2321 ↗
15. 10.1038/s41586-020-2852-110.1038/s41586-020-2852-1 ↗
16. 10.1016/j.cell.2022.05.01410.1016/j.cell.2022.05.014 ↗
17. Huo J. · CellHost. Microbe. · 2020 · 28 · 497
18. 10.1038/s41594-020-0480-y10.1038/s41594-020-0480-y ↗
19. 10.1038/nature1200510.1038/nature12005 ↗
20. 10.1038/nature0214510.1038/nature02145 ↗
21. 10.1126/science.abq083910.1126/science.abq0839 ↗
22. Cohen A. A. · Science. · 2021 · 371 · 73
23. 10.3389/fimmu.2019.0095610.3389/fimmu.2019.00956 ↗
24. 10.1016/j.cell.2020.10.04310.1016/j.cell.2020.10.043 ↗
25. 10.1126/science.aaf881810.1126/science.aaf8818 ↗
26. 10.1021/acsnano.8b0280510.1021/acsnano.8b02805 ↗
27. 10.1038/nature1220210.1038/nature12202 ↗
28. 10.1016/j.cell.2015.07.04310.1016/j.cell.2015.07.043 ↗
29. 10.1038/s41590-018-0305-x10.1038/s41590-018-0305-x ↗
30. 10.1126/sciimmunol.aba646610.1126/sciimmunol.aba6466 ↗
31. 10.1016/j.immuni.2022.10.01910.1016/j.immuni.2022.10.019 ↗
32. 10.1038/s41586-022-05053-w10.1038/s41586-022-05053-w ↗
33. 10.1016/j.cell.2022.06.00510.1016/j.cell.2022.06.005 ↗
34. 10.1016/j.cell.2020.06.01010.1016/j.cell.2020.06.010 ↗
35. 10.1126/science.abc473010.1126/science.abc4730 ↗
36. 10.1038/s41586-022-04441-610.1038/s41586-022-04441-6 ↗
37. Teo S. P. · J. Pharm. Pract. · 2021
38. 10.1038/s41541-021-00292-w10.1038/s41541-021-00292-w ↗
39. Heidary M. · FrontMicrobiol. · 2022 · 13
40. 10.1038/s41541-021-00393-610.1038/s41541-021-00393-6 ↗
41. 10.1073/pnas.220842512010.1073/pnas.2208425120 ↗